- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07398066
DEXmedetomidina per Analgesia Postoperatoria e Prevenzione del Delirio dopo Neurochirurgia (Studio DEX-NEURO) (DEX-NEURO)
DEXmedetomidina per Analgesia Postoperatoria e Prevenzione del Delirio dopo NEUROchirurgia: Uno Studio Randomizzato in Doppio Cieco Controllato con Placebo (Studio DEX-NEURO)
Post-craniotomy pain is common and often undertreated. Inadequate analgesia can lead to patient discomfort and higher opioid consumption, which may result in respiratory depression, sedation risks and impaired neurological assessment in the early postoperative period. The incidence of post-operative delirium after intracranial surgery was 19%, ranging from 12 to 26% caused by variation in clinical features and delirium assessment methods1. It is associated with increased morbidity, longer length of hospital stay, and harm to self or staffs.
Dexmedetomidine (Precedex) is a highly selective α2-adrenergic agonist with the properties of analgesia, sedative, anxiolytic and neuroprotection without significant respiratory depression. Most of the trials administered a loading dose of 0.5-1.0 μg/kg intravenous dexmedetomidine over 10 minutes followed by infusion dose 0.2-0.7 μg/kg/hour. The use of intraoperative dexmedetomidine is believed to reduce the usage of postoperative opioids where frequent neurological assessment is often required in neurosurgical patients. Beyond the benefit of analgesia, perioperative dexmedetomidine has been studied for prevention of postoperative delirium. Randomized trials in mixed noncardiac surgical populations reported that low-dose perioperative dexmedetomidine may reduce the incidence of delirium. Dexmedetomidine produces dose-dependent bradycardia and hypotension, which should be carefully monitored to maintain the cerebral perfusion pressure in brain surgery. However, most trials and meta-analyses have focused on general surgical or cardiac cohorts; the evidence remains limited in neurosurgical (craniotomy) patients.
Although it showed promising benefits of analgesia and neuroprotection in non-neurosurgical patients, recent meta-analyses of intraoperative dexmedetomidine reported high degree of heterogeneity due to the inclusion of varied procedures (elective vs emergent craniotomy), dosing regimes (loading dose only versus loading dose + infusion versus infusion only) and varied primary endpoints (postoperative pain scores, cumulative opioid consumption or incidence of delirium). Therefore, this randomized, double-blind, placebo-controlled trial is designed to examine the use of intravenous dexmedetomidine in the reduction of postoperative pain score and delirium in neurosurgical patients. We hypothesised that intravenous dexmedetomidine reduces postoperative pain score and delirium with lower need of rescue analgesia and amount of morphine consumption in patients undergoing craniotomy.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
There are several similar studies been conducted in the literature search. However, the majority of the studies focus on the intensive care unit patient or non-neurosurgery patients. It is believed that intravenous dexmedetomidine can reduce the postoperative pain score with lesser need for rescue analgesia and morphine consumption to facilitate postoperative neurological assessment.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Ka Ting Dr Ng, MBChB
- Numero di telefono: +60379492411
- Email: katingng1@gmail.com
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- All adult (American Society of Anaesthesiologists (ASA 1-2) who >18 years old and <65 years old undergoing elective craniotomy
Exclusion Criteria:
- Patients who are ASA 3-5 or BMI <18/ >40 or allergic to dexmedetomidine will be excluded. Patients with high-grade heart block or uncontrolled bradyarrhythmia will also be excluded.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Intravenous dexmedetomidine
Intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour |
intravenous dexmedetomidine loading dose 0.5mcg/kg followed by 0.5mcg/kg/hour
Altri nomi:
|
|
Comparatore placebo: Intravenous normal saline
intravenous normal saline loading and infusion dose |
Intravenous normal saline loading and infusion dose of normal saline |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Postoperative pain score at recovery area
Lasso di tempo: In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Numerical Rating Scale (0 no pain-10 most pain) |
In the recovery area after pushing out from the operation theatre (Post-operative 1-hour, Day 1, Day 2)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Need of rescue analgesia
Lasso di tempo: In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
Need to receive additional analgesia (bolus of ketamine, fentanyl, morphine) in the recovery area |
In the recovery area after pushing out from operation theatre (Post-operative 1-hour)
|
|
Total usage of postoperative morphine use in the first 24-hour
Lasso di tempo: In the first 24-hour after surgery in neurointensive care unit
|
The amount of morphine usage in milligram |
In the first 24-hour after surgery in neurointensive care unit
|
|
Postoperative nausea or vomiting
Lasso di tempo: Within the first 24-hour in neurointensive care unit
|
Incidence of nausea or vomiting in the first 24-hour in neurointensive care unit |
Within the first 24-hour in neurointensive care unit
|
|
Incidence of delirium
Lasso di tempo: Day-1 and Day-2 in neurointensive care unit
|
Assessed by CAM-ICU scoring test |
Day-1 and Day-2 in neurointensive care unit
|
|
Patient satisfaction scale of analgesia control
Lasso di tempo: Day-1 in neurointensive care unit
|
Numerical rating scale (0 not satisfy - 10 very satisfy) |
Day-1 in neurointensive care unit
|
|
Adverse events of dexmedetomidine (hypotension and bradycardia).
Lasso di tempo: During surgery when intravenous dexmedetomidine is started
|
systolic blood pressure < 90, heart rate <60 |
During surgery when intravenous dexmedetomidine is started
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Pubblicazioni generali
- Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.
- Li X, Yang J, Nie XL, Zhang Y, Li XY, Li LH, Wang DX, Ma D. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS One. 2017 Feb 9;12(2):e0170757. doi: 10.1371/journal.pone.0170757. eCollection 2017.
- Zhao LH, Shi ZH, Chen GQ, Yin NN, Chen H, Yuan Y, Cao W, Xu M, Hao JJ, Zhou JX. Use of Dexmedetomidine for Prophylactic Analgesia and Sedation in Patients With Delayed Extubation After Craniotomy: A Randomized Controlled Trial. J Neurosurg Anesthesiol. 2017 Apr;29(2):132-139. doi: 10.1097/ANA.0000000000000260.
- Bielka K, Kuchyn I, Babych V, Martycshenko K, Inozemtsev O. Dexmedetomidine infusion as an analgesic adjuvant during laparoscopic small es, Cyrillicholecystectomy: a randomized controlled study. BMC Anesthesiol. 2018 Apr 20;18(1):44. doi: 10.1186/s12871-018-0508-6.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Manifestazioni neurologiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Disordini mentali
- Neoplasie per sede
- Neoplasie
- Neoplasie per tipo istologico
- Confusione
- Manifestazioni neurocomportamentali
- Disturbi neurocognitivi
- Neoplasie, tessuto nervoso
- Neoplasie del sistema nervoso
- Neoplasie, tessuto vascolare
- Neoplasie meningee
- Neoplasie del sistema nervoso centrale
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Dolore
- Delirio
- Meningioma
- Neoplasie cerebrali
- Composti eterociclici, 1-anello
- Composti eterociclici
- Preparati farmaceutici
- Azoli
- Imidazoli
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Dexmedetomidina
- Soluzione salina
Altri numeri di identificazione dello studio
- 16023
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .